title: Novel downstream molecular targets of SIRT1 in melanoma: a quantitative proteomics approach.
abstract: Melanoma is one of the most lethal forms of skin cancer and its incidence is continuing to rise in the United States. Therefore, novel mechanism and target-based strategies are needed for the management of this disease. SIRT1, a NAD(+)-dependent class III histone deacetylase, has been implicated in a variety of physiological processes and pathological conditions. We recently demonstrated that SIRT1 is upregulated in melanoma and its inhibition by a small-molecule, tenovin-1, inhibits cell proliferation and clonogenic survival of melanoma cells, possibly via activating p53. Here, we employed a gel free quantitative proteomics approach to identify the downstream effectors and targets of SIRT1 in melanoma. The human malignant melanoma, G361 cells were treated with tenovin-1 followed by protein extraction, in liquid trypsin digestion, and peptide analyses using nanoLC-MS/MS. A total of 1091 proteins were identified, of which 20 proteins showed significant differential expression with 95% confidence interval. These proteins were subjected to gene ontology and Ingenuity Pathway Analysis (IPA) to obtain the information regarding their biological and molecular functions. Real-Time qRT-PCR validation showed that five of these (PSAP, MYO1B, MOCOS, HIS1H4A and BUB3) were differentially expressed at mRNA levels. Based on their important role in cell cycle regulation, we selected to focus on BUB family proteins (BUB3, as well as BUB1 and BUBR1) for subsequent validation. The qRT-PCR and immunoblot analyses showed that tenovin-1 inhibition of SIRT1 resulted in a downregulation of BUB3, BUB1 and BUBR1 in multiple melanoma cell lines. Since tenovin-1 is an inhibitor of both SIRT1 and SIRT2, we employed lentivirus mediated silencing of SIRT1 and SIRT2 in G361 cells to determine if the observed effects on BUB family proteins are due to SIRT1- or SIRT2- inhibition. We found that only SIRT1 inhibition resulted in a decrease in BUB3, BUB1 and BUBR1. Our study identified the mitotic checkpoint regulator BUB family proteins as novel downstream targets of SIRT1. However, further validation is needed in appropriate models to confirm our findings and expand on our observations.
authors.affiliation: Department of Dermatology, University of Wisconsin, Madison, WI.
authors.forename: Chandra K
authors.initials: CK
authors.lastname: Singh
authors.forename: Jasmine
authors.initials: J
authors.lastname: George
authors.forename: Minakshi
authors.initials: M
authors.lastname: Nihal
authors.forename: Grzegorz
authors.initials: G
authors.lastname: Sabat
authors.forename: Raj
authors.initials: R
authors.lastname: Kumar
authors.forename: Nihal
authors.initials: N
authors.lastname: Ahmad
mesh_terms: D000083:Acetanilides / Q000494:pharmacology; D018797:Cell Cycle Proteins / Q000235:genetics; D045744:Cell Line, Tumor; D015536:Down-Regulation; D004789:Enzyme Activation / Q000187:drug effects; D063990:Gene Ontology; D020868:Gene Silencing; D056572:Histone Deacetylase Inhibitors / Q000494:pharmacology; D006657:Histones / Q000235:genetics; D006801:Humans; D008545:Melanoma / Q000201:enzymology* / Q000235:genetics*; D024461:Myosin Type I / Q000235:genetics; D000075223:Poly-ADP-Ribose Binding Proteins; D017346:Protein Serine-Threonine Kinases / Q000235:genetics; D040901:Proteomics; D012333:RNA, Messenger / Q000378:metabolism*; D049231:Saposins / Q000235:genetics; D056564:Sirtuin 1 / Q000235:genetics / Q000378:metabolism*; D013466:Sulfurtransferases / Q000235:genetics; D013890:Thiourea / Q000031:analogs & derivatives / Q000494:pharmacology
chemical_list: D000083:Acetanilides; C489444:BUB3 protein, human; D018797:Cell Cycle Proteins; D056572:Histone Deacetylase Inhibitors; D006657:Histones; C000594736:MYO1B protein, human; C483345:PSAP protein, human; D000075223:Poly-ADP-Ribose Binding Proteins; D012333:RNA, Messenger; D049231:Saposins; C000594735:tenovin-1; C584277:BUB1 protein, human; D017346:Protein Serine-Threonine Kinases; C425823:MOCOS protein, human; D013466:Sulfurtransferases; C447939:SIRT1 protein, human; D056564:Sirtuin 1; D024461:Myosin Type I; D013890:Thiourea
references.citation: Oncogene. 2014 Mar 27;33(13):1609-20
references.pmid: 23604120
references.citation: Trends Pharmacol Sci. 2010 May;31(5):212-20
references.pmid: 20226541
references.citation: Ann N Y Acad Sci. 2012 Oct;1271:10-9
references.pmid: 23050959
references.citation: Anal Chem. 2002 Oct 15;74(20):5383-92
references.pmid: 12403597
references.citation: Comb Chem High Throughput Screen. 2012 Mar;15(3):221-31
references.pmid: 22221055
references.citation: Nucleic Acids Res. 2012 Jan;40(Database issue):D1144-9
references.pmid: 22086960
references.citation: Discov Med. 2010 Feb;9(45):145-52
references.pmid: 20193641
references.citation: CA Cancer J Clin. 2012 Jul-Aug;62(4):220-41
references.pmid: 22700443
references.citation: Arch Dermatol Res. 2007 May;299(2):103-6
references.pmid: 17180656
references.citation: Adv Exp Med Biol. 2008;624:265-82
references.pmid: 18348463
references.citation: Anal Chem. 2003 Sep 1;75(17):4646-58
references.pmid: 14632076
references.citation: Clin Cancer Res. 2006 Jan 15;12(2):405-10
references.pmid: 16428479
references.citation: J Biol Chem. 2009 Feb 6;284(6):3823-32
references.pmid: 19075016
references.citation: Cell Cycle. 2008 Apr 15;7(8):1001-5
references.pmid: 18414023
references.citation: J Pathol. 2003 May;200(1):16-22
references.pmid: 12692836
references.citation: Cell Oncol. 2008;30(5):389-95
references.pmid: 18791270
references.citation: Genome Biol. 2004;5(5):224
references.pmid: 15128440
references.citation: Curr Opin Oncol. 2012 Jan;24(1):68-75
references.pmid: 22080944
references.citation: Drug Resist Updat. 2007 Aug-Oct;10(4-5):162-81
references.pmid: 17669681
references.citation: Curr Opin Genet Dev. 2011 Feb;21(1):21-8
references.pmid: 21071203
references.citation: PLoS One. 2013 Sep 03;8(9):e74738
references.pmid: 24019980
references.citation: Trends Biochem Sci. 2013 Mar;38(3):160-7
references.pmid: 23394938
references.citation: Trends Biochem Sci. 2011 Mar;36(3):141-50
references.pmid: 20888775
references.citation: Front Pharmacol. 2012 Jan 31;3:4
references.pmid: 22319497
references.citation: BMC Cancer. 2013 Oct 02;13:450
references.pmid: 24088390
references.citation: PLoS One. 2012;7(9):e45119
references.pmid: 23024800
references.citation: Cancer Cell. 2008 May;13(5):454-63
references.pmid: 18455128
references.citation: Cell Cycle. 2014;13(4):632-40
references.pmid: 24343700
references.citation: J Biol Chem. 2012 Dec 14;287(51):42444-52
references.pmid: 23086954
references.citation: Mol Cell Biol. 2011 Aug;31(15):3085-93
references.pmid: 21628528
references.citation: Curr Pharm Des. 2013;19(4):614-23
references.pmid: 23016857
references.citation: Int J Proteomics. 2013;2013:180605
references.pmid: 23533757
references.citation: Oncotarget. 2012 Oct;3(10):1182-93
references.pmid: 23045412
references.citation: PLoS One. 2012;7(9):e45513
references.pmid: 23049808
references.citation: J Assist Reprod Genet. 2011 Feb;28(2):173-88
references.pmid: 20953827
references.citation: Cancer Res. 2012 Aug 1;72(15):3864-72
references.pmid: 22593191
references.citation: Oncol Rep. 2013 Jan;29(1):185-92
references.pmid: 23128493
references.citation: Onco Targets Ther. 2013 Oct 08;6:1399-416
references.pmid: 24133372
references.citation: Hum Pathol. 2011 Feb;42(2):204-13
references.pmid: 21056897
references.citation: Int J Biol Sci. 2009;5(2):147-52
references.pmid: 19173036
references.citation: Childs Nerv Syst. 2013 Dec;29(12):2241-8
references.pmid: 23728478
references.citation: J Histochem Cytochem. 2013 May;61(5):330-9
references.pmid: 23392733
references.citation: Cell Cycle. 2008 Jun 15;7(12):1763-8
references.pmid: 18594200
references.citation: Arch Biochem Biophys. 2014 Dec 1;563:94-100
references.pmid: 24751483
references.citation: CA Cancer J Clin. 2013 Jan;63(1):11-30
references.pmid: 23335087